Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin versus phenobarbital for neonatal opioid withdrawal syndrome
IRCT20250815066860N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gabapentin, phenobarbital and morphine in neonatal opioid withdrawal syndrome (NOWS) and neonatal abstinence syndrome (NAS) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Length of hospitalization, Duration of treatment and 2 more. Started Apr 2025; status: completed.
02
Drugs
gabapentinphenobarbitalmorphine
03
Conditions
neonatal opioid withdrawal syndrome (NOWS)neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on IRCT20250815066860N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250815066860N1.